Newsroom

Propeller Health’s precision digital health platform wins the Clinical Information Management category of the Fierce Healthcare Innovation Awards 2022. The platform enables physicians and care teams to proactively identify at-risk patients in between routine visits and provide more timely clinical interventions.

MADISON, WI, November 15, 2022 – Propeller Health, a leader in precision digital health, today announces its platform for chronic condition management is a Fierce Healthcare Innovation Awards 2022 winner. The program showcases outstanding innovation that is driving improvements and transforming the industry. The Propeller Digital Health Platform for Chronic Condition Management (The Propeller Platform”) enables proactive clinical care by collecting objective patient data and displaying resulting insights directly within a provider’s native workflow. 

At Propeller, data itself is only the beginning – activating it is what powers patient care,” said Susa Monacelli, Propeller Health General Manager. By surfacing the data within clinicians’ existing workflow through EHR integrations, we enable their treatment decisions and help identify at-risk patients. Patient self-management coupled with proactive clinician intervention helps improve clinical outcomes and, in turn, economic value for health systems, payers, and patients. Our focus is to do this across connected medications and therapies to change healthcare at scale.”

Announces integrations with multiple leading Electronic Health Record (EHR) systems, introduces a new solution to enable Remote Therapeutic Monitoring (RTM) by healthcare providers, and launches digital platform updates to enable respiratory care at home, in-clinic, and on-the-go.

MIAMI, March 7, 2022 – Propeller Health, a leader in digital health for asthma and chronic obstructive pulmonary disease (COPD), today announced three exciting updates and new solutions to bring its clinically proven, FDA-cleared platform to more patients, providers and health systems.

Integrations expand the reach of Propeller’s digital platform to more health systems

News Announcement at HLTH 2021, Boston MA, October 18, 2021 MADISON, Wisconsin, October 18, 2021 – Propeller Health, a leader in digital health and therapeutics for asthma and chronic obstructive pulmonary disease (COPD), revealed two recent studies that showed that digital health interventions alongside appropriate care resources and tools can expand access and improve outcomes for elderly and underserved populations. Propeller’s digital health platform includes Bluetooth® connected inhaler sensors that chime medication reminders and record inhaler medication use, paired with a smartphone app that provides education and feedback to support self-management. In a study¹ conducted in partnership with Desert Oasis Healthcare, Propeller evaluated the effect of digital health intervention on healthcare resource utilization and medication use in patients with COPD. 56 patients with COPD, average age 75, were enrolled by their clinical pharmacists, who received alerts through Propeller’s clinician portal whenever patients showed low controller medication adherence or high rescue inhaler use.

Integrating data from the Propeller platform into Dignity Health’s EHR improves clinical and operational efficiencies and provides physicians with real-time insights to improve patient treatment decisions. SAN FRANCISCO – October 5, 2021 – Dignity Health, which is part of 21-state health system CommonSpirit Health, and Propeller Health, a leader in digital health and therapeutics for asthma and chronic obstructive pulmonary disease (COPD), announced today that they have integrated Propeller’s platform into Dignity Health’s electronic health record (EHR) system. This integration has been fully implemented in seven communities served by Dignity Health physicians and clinics in Arizona and California. With the EHR integration, Dignity Health and Propeller could potentially scale the tool to hundreds of physicians who care for thousands of patients with an eligible diagnosis. Now, the Propeller solution can be ordered and managed through the EHR like any other medication or treatment. Enrollment is streamlined for providers and staff as they don’t have to leave their clinical workflow: it now takes two minutes to enroll a patient, which is a 75-80% reduction in time.

Patients will use Propeller’s digital health tools to manage symptoms and increase adherence, in partnership with Desert Oasis’ team of clinical pharmacists June 8, 2021 – Propeller Health today announced an expanded partnership with Palm Springs, Calif. based Desert Oasis Healthcare (DOHC) to increase inhaler adherence, decrease rescue use, and lower healthcare costs for people with asthma and COPD. The partnership with DOHC expands the use of Propeller’s digital health solution among high-risk COPD patients, who experience avoidable hospitalizations and ER visits at a greater rate than the general population and who can benefit from digital health intervention to manage their symptoms. Through this collaboration, Propeller will be available to over 700 people with asthma and COPD, the majority of them high-risk COPD patients.

Asthma and COPD medication adherence was lowest in young adults, highest in children and older adults MADISON, Wisc., January 26, 2021 – Adherence to asthma and COPD medication differs significantly by age, diagnosis and other demographics, suggesting an opportunity to tailor adherence education to each patient, according to new research from Propeller Health.

Patients also used their rescue inhalers less often with the help of a digital health tool, according to new research MADISON, Wisc., November 19, 2020 – Patients using Propeller Health to manage their asthma experienced a significant decline in rescue inhaler use and higher medication adherence rates compared to patients not using the platform, according to a new randomized controlled trial published in The Journal of Allergy and Clinical Immunology: In Practice by researchers from Propeller and NorthShore University HealthSystem.

Patients in Japan using Enerzair® and Atectura® Breezhaler® to treat uncontrolled asthma will now have access to Propeller’s digital health platform through their clinician Propeller Health today announced it will begin distributing in Japan, via a collaboration with Novartis to connect the Propeller digital health platform to Enerzair® and Atectura® Breezhaler®, two new once-daily Novartis medications available outside the U.S. to treat uncontrolled asthma.

Enerzair® Breezhaler® plus sensor is the first asthma medication to be co-packaged and co-prescribed with a digital health platform MADISON, Wisc., July 7, 2020 – Propeller Health today announced a collaboration with Novartis to co-package the Propeller digital health platform with Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]), a recently approved Novartis medication developed to treat uncontrolled asthma.